Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
MPLT
MapLight Therapeutics, Inc.
CAPPED RATING
MapLight Therapeutics, Inc. (MPLT) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Overall Rating
2.0
/ 5.0
C-
Value
C+
Factor Score
2.5
/ 5.0
Growth
C
Factor Score
2.3
/ 5.0
Profitability
D+
Factor Score
1.6
/ 5.0
Momentum
D
Factor Score
1.2
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-2.1
EV / EBITDA
-0.1
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-39.8%
Price Return 12M
-53.1%
Catalyst Signal
0.00
Market Cap
$392.9M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-111.5%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C (2.3) | D+ (1.6) | D (1.2) | C+ (2.6) | C- (2.0) |
| 2026-11-06 | A- (3.9) | C (2.2) | D+ (1.7) | D- (1.1) | F (0.0) | D+ (1.8) |
| 2026-10-30 | C+ (2.5) | C (2.2) | D+ (1.7) | D- (1.1) | F (0.0) | D+ (1.5) |
| 2026-10-23 | C+ (2.5) | C (2.3) | D+ (1.7) | D- (0.7) | F (0.0) | D (1.4) |
| 2026-10-16 | C+ (2.5) | C (2.3) | D+ (1.7) | D- (0.7) | F (0.0) | D (1.4) |
Page
1
of
4